Plain-English translation of NCT04634552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is one of the first times this treatment has been tested in people.
This study is testing an experimental medication called , which works by helping your immune system recognize and attack myeloma cancer cells. The medication is given as an injection under the skin. Researchers want to learn whether this treatment is safe and effective for people whose multiple myeloma has come back or stopped responding to other therapies.
Multiple myeloma is a serious blood cancer that can become resistant to standard treatments, leaving patients with limited options. This trial exists to determine if this new type of immune therapy can help patients whose cancer has proven difficult to treat with conventional approaches.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication under your skin at a dose determined to be safe and effective from earlier parts of the study. You will have regular visits to check your health, measure your cancer response, and monitor for any side effects. If the treatment is working well and tolerated, you may be able to continue receiving it in an extended phase of the study that can last months to years.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
United States